Just Released – Canadian Cancer Statistics 2022

/0 Comments/in /by
The Canadian Cancer Society is pleased to inform you this year’s Canadian Cancer Statistics publication was developed in the form of a peer-reviewed article Projected estimates of cancer in Canada in 2022, which was published in the Canadian Medical Association Journal (CMAJ) on May 2, 2022. The article provides 2022 (more…)

CCS Accelerator Grants

/0 Comments/in , /by
View the full funding opportunity here. The overarching goal of this funding program is to accelerate the application of high-quality evidence that is meaningful to people affected by cancer in the near term (i.e. 2-5 years). Through the Accelerator Grants, CCS will support research that addresses one of the following: (more…)

TFRI – Chief Data Officer

/0 Comments/in , /by
View this posting on the TFRI website by clicking here The Terry Fox Research Institute (TFRI), named for Canadian icon Terry Fox, is built on Terry’s dream to end cancer through research. Established in 2007, TFRI invests in world-class, collaborative cancer research teams and partnerships. Together with its research and (more…)

Senior Manager – Research Programs

/0 Comments/in , /by
For full detail and instructions how to apply, click here JOB OVERVIEW Reporting to the Director, Research Operations, the Senior Manager, Research Programs provides senior-level support in strategic planning and management of the Canadian Cancer Society’s (CCS) research programs. Key responsibilities are grouped according to the following categories: Management of (more…)
The Canadian Centre for Applied Research in Cancer Control

Impact of cancer surgery slowdowns on patient survival during the COVID-19 pandemic: a microsimulation modelling study

/0 Comments/in /by
A new article has been published by a group of ARCC researchers  shows that #COVID19 related slowdowns of cancer surgeries could affect long-term survival for many patients with cancer. Authors: Ambica Parmar MD MSc, Antoine Eskander MD ScM, Beate Sander RN PhD, David Naimark MD MSc, Jonathan C. Irish MD (more…)

Senior Research Fellow/Associate Professor HTA role: The University of Melbourne

/0 Comments/in , /by
Job no: 0054026 Location: Parkville Role type: Full time;  Fixed-term for 3 years Faculty: Faculty of Medicine, Dentistry and Health Sciences Department/School: Melbourne School of Population and Global Health Salary ($AUD): Level C – $131,739 – $151,900/Level D – $158,624 – $174,754 p.a. plus 17% super For full details or to apply online click here About the (more…)

CADTH Call For Nominations

/0 Comments/in , /by
CADTH is seeking nominations for its expert and advisory committees. They are currently accepting applications from individuals with significant expertise in the Canadian health care system who are interested in helping support health care decision-makers in making informed choices about health technologies. In total, CADTH is seeking 16 new members (more…)

New Publication: Comparative Effectiveness and Safety of Pertuzumab and Trastuzumab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy for Treatment of Metastatic Breast Cancer

/0 Comments/in , /by
We are happy to announce that CanREValue’s latest publication, Comparative Effectiveness and Safety of Pertuzumab and Trastuzumab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy for Treatment of Metastatic Breast Cancer, has been accepted for publication in JAMA Network Open. Download a copy of this paper. Abstract IMPORTANCE: To date, limited studies (more…)
Canadian Partnership Against Cancer logo

Manager, Research & Innovation, Canadian Partnership Against Cancer

/0 Comments/in , /by
Reports to: Director, Research & Innovation Location: Downtown Toronto (work from home until the expected return to the office in 2022) Posting date: March 9, 2022 Closing date: March 23, 2022 For full details and to apply click here The Partnership is looking for a Manager, Research and Innovation, a key member (more…)

New Publication: Cost-effectiveness Analysis of Pertuzumab With Trastuzumab in Patients With Metastatic Breast Cancer

/0 Comments/in , /by
We are happy to announce that CanREValue’s latest publication, Cost-effectiveness Analysis of Pertuzumab With Trastuzumab in Patients With Metastatic Breast Cancer, has been accepted for publication in JAMA Oncology. Download a copy of this paper. Abstract IMPORTANCE: The initial assessment of pertuzumab use for treatment of metastatic breast cancer by (more…)